Association Between Human Leukocyte Antigen E Expression and Outcomes in Solid Tumors: a Systematic Review and Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Mar 11

PMID 40066089

Authors

Javier David Benitez Fuentes

Jorge Bartolome Arcilla

Antonio David Lazaro Sanchez

Alicia de Luna Aguilar

Kauzar Mohamed Mohamed

Kissy Guevara-Hoyer

Pablo Ballestin Martinez

Miguel Borregon Rivilla

Asia Ferrandez Arias

Silvia Sanchez-Ramon

Alberto Ocana

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapy has gained momentum with the discovery of novel antibodies targeting immunosuppressive proteins. HLA-E, a non-classical major histocompatibility complex class I (MHC-I) protein, exhibits immunosuppressive properties, potentially influencing tumor immune evasion mechanisms. The association between Human Leukocyte Antigen E (HLA-E) expression and outcomes in solid tumors remains unclear.

Methods: A systematic review of MEDLINE, Scopus, and the Cochrane Library up to March 15, 2024, was conducted following the PRISMA guidelines. Studies investigating HLA-E expression in solid tumors and its association with OS and DFS were included. Statistical analysis was performed using Comprehensive Meta-Analysis (version 3.0) with random-effects models.

Results: After screening 657 articles, 11 studies were included, comprising a total of 1781 patients. The studies encompassed a variety of cancer types, follow-up periods, and staging details, with the majority focusing on non-metastatic cases. Notably, three studies evaluated colorectal cancer, while others focused on pancreatic, esophageal, brain, renal cell, gastric, endometrial, cervical, and hepatocellular carcinomas. The mean age of the patients was 59.81 ± 2.01 years, and the median follow-up period was 57.45 ± 8.91 months. HLA-E expression demonstrated no statistically significant association with OS (HR 0.913, 95% CI = 0.567-1.469; P=0.707), with significant heterogeneity observed (I2 = 84%). However, HLA-E non-expression was significantly associated with improved DFS (HR 1.406, 95% CI = 1.027-1.930; P=0.03), with moderate heterogeneity (I2 = 45%).

Conclusion: This systematic review highlights that HLA-E expression in solid tumors could be a biomarker of better prognosis, measured by DFS. These findings align with the clinical benefit observed for agents targeting this pathway. However, further studies should be performed to confirm these preliminary observations.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024527598, identifier CRD42024527598.

References

Benitez Fuentes J, Bartolome Arcilla J, Mohamed Mohamed K, Lopez de Sa A, de Luna Aguilar A, Guevara-Hoyer K . Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer. Cancers (Basel). 2025; 16(24. PMC: 11675049. DOI: 10.3390/cancers16244266. View

Levy E, Bianchini M, von Euw E, Barrio M, Bravo A, Furman D . Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008; 32(3):633-41. View

Liu X, Xi X, Xu S, Chu H, Hu P, Li D . Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer. Front Immunol. 2024; 15:1507501. PMC: 11669709. DOI: 10.3389/fimmu.2024.1507501. View

van Esch E, Tummers B, Baartmans V, Osse E, Ter Haar N, Trietsch M . Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer. 2014; 135(4):830-42. DOI: 10.1002/ijc.28713. View

Zhen Z, Ling J, Cai Y, Luo W, He Y . Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol. 2013; 30(1):482. DOI: 10.1007/s12032-013-0482-2. View

de Kruijf E, Sajet A, van Nes J, Natanov R, Putter H, Smit V . HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol. 2010; 185(12):7452-9. DOI: 10.4049/jimmunol.1002629. View

Llano M, Lee N, Navarro F, Garcia P, Albar J, Geraghty D . HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998; 28(9):2854-63. DOI: 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W. View

Zheng H, Guan X, Meng X, Tong Y, Wang Y, Xie S . IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis. J Ovarian Res. 2023; 16(1):229. PMC: 10675946. DOI: 10.1186/s13048-023-01286-z. View

Wyatt R, Lanzoni G, Russell M, Gerling I, Richardson S . What the HLA-I!-Classical and Non-classical HLA Class I and Their Potential Roles in Type 1 Diabetes. Curr Diab Rep. 2019; 19(12):159. PMC: 6901423. DOI: 10.1007/s11892-019-1245-z. View

10.

Ravindranath M, Pham T, El-Awar N, Kaneku H, Terasaki P . Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies. Mol Immunol. 2010; 48(4):423-30. DOI: 10.1016/j.molimm.2010.09.011. View

11.

Hazini A, Fisher K, Seymour L . Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021; 9(8). PMC: 8344275. DOI: 10.1136/jitc-2021-002899. View

12.

Chu G, Jiao W, Yang X, Liang Y, Li Z, Niu H . , , , and as potential prognostic biomarkers for renal clear cell carcinoma. Transl Androl Urol. 2021; 9(6):2640-2656. PMC: 7807358. DOI: 10.21037/tau-20-699. View

13.

Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A . Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006; 177(5):3100-7. DOI: 10.4049/jimmunol.177.5.3100. View

14.

Andersson E, Poschke I, Villabona L, Carlson J, Lundqvist A, Kiessling R . Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology. 2016; 5(1):e1052213. PMC: 4760332. DOI: 10.1080/2162402X.2015.1052213. View

15.

Guberina H, Rebmann V, Wagner B, da Silva Nardi F, Dziallas P, Dolff S . Association of high HLA-E expression during acute cellular rejection and numbers of HLA class I leader peptide mismatches with reduced renal allograft survival. Immunobiology. 2016; 222(3):536-543. DOI: 10.1016/j.imbio.2016.10.021. View

16.

Xu S, Chen X, Ying H, Chen J, Ye M, Lin Z . Multi‑omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma. BMC Cancer. 2024; 24(1):1138. PMC: 11395699. DOI: 10.1186/s12885-024-12911-5. View

17.

Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T . Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018; 175(7):1731-1743.e13. PMC: 6292840. DOI: 10.1016/j.cell.2018.10.014. View

18.

Xu Y, Du X, Li Z, Fang Z, Zhang F . Lesion human leukocyte antigen-E is associated with favourable prognosis for patients with oesophageal squamous cell carcinoma. J Int Med Res. 2021; 49(10):3000605211047278. PMC: 8504691. DOI: 10.1177/03000605211047278. View

19.

Wang X, Liao X, Yang C, Yu T, Liu Z, Gong Y . Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma. J Cancer. 2019; 10(21):5173-5190. PMC: 6775598. DOI: 10.7150/jca.29655. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View